Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
SOHO 2023
🎥 @calliecoombsmd of @UCIrvineHealth discusses frontline therapy selection for patients with CLL, highlighting how treatment choice may vary based on risk profile:
👉 👈
#CLLsm #Leusm #Leukemia #HemOnc
Approaching frontline therapy selection for different risk groups in CLL
In this video, Catherine Coombs, MD, UC Irvine Health, Orange, CA, discusses frontline therapy selection for patients ...
ow.ly
How may off-the-shelf cellular therapies, such as allo and in vivo CARs, change the treatment landscape in #myeloma?🩸
We asked Karlo Perica (@MSKCancerCenter) this question at #iwHRMM25, and here's what he had to say:
🎥
#MMSM #ImmunoOnc…
How off-the-shelf cellular therapies may change the treatment landscape in myeloma
In this interview, Karlo Perica, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the potent...
ow.ly
At #SOHO2025, we spoke with @GCC_Cortes of @GACancerCenter, who discussed the importance of adjusting the dose and dosing schedule of TKIs in patients with CML.
Watch now:
🎥
#CMLsm #Leusm #Leukemia #HemOnc
Dynamically adjusting the dose and dosing schedule of TKIs in patients with CML
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the importance of adjusting the do...
ow.ly
#IMS25 | Diana Cirstea of @MGHCancerCenter provides insight into the BOSS program, an initiative aimed at improving the safety of bispecific step-up dosing for patients with #myeloma treated in the outpatient setting.
Watch here:
🎥
#MMSM…
The BOSS program: improving the safety of bispecific outpatient step-up dosing for multiple myeloma
Diana Cirstea, MD, Massachusetts Cancer Center, Boston, MA, discusses the BOSS program experience in multiple myeloma, ...
ow.ly
🎥 Letizia Fontana of @InstitutImagine discusses early evidence supporting the efficacy of epigenome editing in #SickleCellDisease & and beta-thalassemia, providing insight into a proof-of-concept study conducted by her team:
👉
#Thalassemia #SickleCell…
Proof-of-concept: using epigenome editing in SCD and beta-thalassemia
Letizia Fontana, PhD, Institut Imagine, Paris, France, discusses early evidence supporting the efficacy of epigenome edi...
ow.ly
SOHO 2023
🎥 @calliecoombsmd of @UCIrvineHealth discusses frontline therapy selection for patients with CLL, highlighting how treatment choice may vary based on risk profile:
👉 👈
#CLLsm #Leusm #Leukemia #HemOnc
Approaching frontline therapy selection for different risk groups in CLL
In this video, Catherine Coombs, MD, UC Irvine Health, Orange, CA, discusses frontline therapy selection for patients ...
ow.ly
How may off-the-shelf cellular therapies, such as allo and in vivo CARs, change the treatment landscape in #myeloma?🩸
We asked Karlo Perica (@MSKCancerCenter) this question at #iwHRMM25, and here's what he had to say:
🎥
#MMSM #ImmunoOnc…
How off-the-shelf cellular therapies may change the treatment landscape in myeloma
In this interview, Karlo Perica, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the potent...
ow.ly
At #SOHO2025, we spoke with @GCC_Cortes of @GACancerCenter, who discussed the importance of adjusting the dose and dosing schedule of TKIs in patients with CML.
Watch now:
🎥
#CMLsm #Leusm #Leukemia #HemOnc
Dynamically adjusting the dose and dosing schedule of TKIs in patients with CML
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the importance of adjusting the do...
ow.ly
#IMS25 | Diana Cirstea of @MGHCancerCenter provides insight into the BOSS program, an initiative aimed at improving the safety of bispecific step-up dosing for patients with #myeloma treated in the outpatient setting.
Watch here:
🎥
#MMSM…
The BOSS program: improving the safety of bispecific outpatient step-up dosing for multiple myeloma
Diana Cirstea, MD, Massachusetts Cancer Center, Boston, MA, discusses the BOSS program experience in multiple myeloma, ...
ow.ly
🎥 Letizia Fontana of @InstitutImagine discusses early evidence supporting the efficacy of epigenome editing in #SickleCellDisease & and beta-thalassemia, providing insight into a proof-of-concept study conducted by her team:
👉
#Thalassemia #SickleCell…
Proof-of-concept: using epigenome editing in SCD and beta-thalassemia
Letizia Fontana, PhD, Institut Imagine, Paris, France, discusses early evidence supporting the efficacy of epigenome edi...
ow.ly
